Brief: Sanofi's Nuvaxovid Covid-19 Vaccine Showed Better Tolerability Than Mnexspike In Head-To-Head Study
18/04/2026 11:42
April 18 (Reuters) - Sanofi SA SASY.PA: REG-PRESS RELEASE: ESCMID: SANOFI'S NUVAXOVID COVID-19 VACCINE SHOWED BETTER TOLERABILITY THAN MNEXSPIKE IN HEAD-TO-HEAD STUDY SANOFI - STUDY MET PRIMARY ENDPOINT WITH SIGNIFICANTLY FEWER SYSTEMIC REACTIONS FOR NUVAXOVID Source text: ID:nGNEbqZTBS Further company coverage: SASY.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sanofi SA
See all newsFDA approves expanded use of Sanofi's type 1 diabetes drug (updated)
Brief: FDA Approves Tzield For Pediatric Stage 3 Type I Diabetes
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
European shares steady as investors weigh US-Iran flare-up (updated)
European shares steady as investors cling to Mideast peace hopes